Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)

• Published in: Clinical & translational immunology Vol. 9; no. 10; pp. e1198 - n/a
• Main Authors: Galeotti, Caroline, Kaveri, Srini V, Bayry, Jagadeesh
• Format: Journal Article
• Language: English
• Published: Australia John Wiley & Sons, Inc 2020; Nature Publishing Group; John Wiley and Sons Inc; Wiley
• Subjects: Allergology; Antibiotics; Antibodies; Antiviral agents; Azithromycin; Cell activation; Coronaviruses; Corticosteroids; COVID-19; Creatine; Creatine kinase; Cytokines; Disease; Drug dosages; Effector cells; Ferritin; Helper cells; Hydrocortisone; Immunoglobulins; Immunology; Immunoregulation; Immunotherapy; Inflammatory diseases; Innate immunity; Interferon; Interleukin 1 receptor antagonist; Intravenous administration; L-Lactate dehydrogenase; Lactic acid; Life Sciences; Lymphocytes T; Mechanical ventilation; Mortality; Oxygen; Oxygen saturation; Oxygenation; Patients; Severe acute respiratory syndrome coronavirus 2; Steroids; Ventilators; United States > US; China
• ISSN: 2050-0068; 2050-0068
• DOI: 10.1002/cti2.1198

Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐controlled, double‐blind randomised clinical trials are lacking, current data from either retrospective, case series or open‐label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID‐19 patients. See alsoShao et al.